[The effect of cytostatic therapy on pyruvate kinase activity in the erythrocytes of patients with acute myelocytic leukemia].
D000255:Adenosine Triphosphate / Q000097:blood; D000293:Adolescent; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D003561:Cytarabine / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D004912:Erythrocytes / Q000201:enzymology*; D005260:Female; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy* / Q000201:enzymology; D008297:Male; D008875:Middle Aged; D011770:Pyruvate Kinase / Q000097:blood*
D003561:Cytarabine; D004317:Doxorubicin; D000255:Adenosine Triphosphate; D011770:Pyruvate Kinase
Utjecaj citostatske terapije na aktivnosti enzima piruvat kinaze u eritrocitu bolesnika s akutnom mijeloicnom leukemijom.